Abstract
Myeloproliferative Neoplasms (MPN) originate from molecular abnormalities at the hematopoietic stem cell (HSC) level, but alterations of the bone marrow niche may also contribute to the functional regulation of the neoplastic stem cells and of the normal residual HSCs and, thus, collaborate to the pathophysiology of the disease. Therefore, considering that these diseases are not only depe…